Enzo Biochem's Clinical Lab and Biotech Leader DiaSorin Collaborate to Provide Advanced Clinical Tec
Enzo Biochem's Clinical Lab and Biotech Leader DiaSorin Collaborate to Provide Advanced Clinical Technologies
Positions Enzo Labs as "Center of Excellence" for Developing DiaSorin Assays
NEW YORK--(BUSINESS WIRE)-- Enzo Biochem, Inc. (NYS: ENZ) today announced its Enzo Clinical Labs unit has entered into a collaboration with Italy-based DiaSorin, a global leader in the field of biotechnologies, that will enable the Lab to provide physician-clients in metropolitan New York with advanced diagnostic tools and will also serve to evaluate new DiaSorin offerings in the future.
"Our agreement with DiaSorin has multiple benefits that, in addition to providing additional cutting edge diagnostic technology to physicians and their patients from a global leader in the in vitro diagnostics field, also reflects an acknowledgement of the excellent and expanding capabilities of our Lab, a center of excellence, in evolving medical science," said Barry Weiner, Enzo President.
As part of the agreement, Enzo Clinical Labs has added two new DiaSorin LIAISON® XL Analyzers, a new high throughput, chemiluminescent, random access analyzer that provides a menu of over 30 assays. The system requires no daily maintenance with most tests and can manage up to 25 different assays on board.
"We are excited to collaborate with Enzo to provide high quality automated testing solutions to best serve their clients with an opportunity for growth and improved patient care," said John Eskdale, DiaSorin President. "The LIAISON® XL, with its expanded menu, will offer Enzo a competitive advantage in the areas of specialty testing which include infectious disease, growth, hypertension, and bone & mineral."
Enzo Labs initially will offer a number of DiaSorin LIAISON® XL tests to its customers, including the LIAISON® 25 OH Vitamin D TOTAL assay, which measures both 25-OH D2 and 25-OH D3 metabolites to accurately assess Vitamin D sufficiency. Enzo will also offer DiaSorin's CMV IgM and Borrelia burgdorferi assays, and is currently evaluating the company's new LIAISON® Direct Renin and Aldosterone assays. These tests are the only fully automated, FDA cleared chemiluminescent assays available for the diagnosis and treatment of certain types of hypertension and primary aldosteronism.
Enzo and DiaSorin will continue to evaluate the entire line of LIAISON® assays to assure Enzo's clientele of the availability of the most advanced and high quality immunoassays.
About Enzo Biochem
Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of health care both today and into the future. Underpinning Enzo Biochem's products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
For over 40 years, DiaSorin Company has been developing, manufacturing and marketing reagent kits for in vitro diagnostics worldwide, and offers the broadest range of specialty tests available in the immunodiagnostics market. DiaSorin's menu is unique for its breadth and presence of specialty tests which identify DiaSorin as "the" in vitro diagnostics specialist, and it is the exclusive supplier of the LIAISON® platform, a closed system based on chemiluminescent technology that is fully automated. The Company continually invests in research and development, using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation.
Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses are dependent on a number of factors outside of the control of the company including, inter alia, the markets for the Company's products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. See Risk Factors in the Company's Form 10-K for the fiscal year ended July 31, 2013. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.
For Enzo Biochem, Inc.
Anreder & Company
Steven Anreder, 212-532-3232
Michael Wachs, 212-732-4300
Riccardo Fava, +39.0161.487988
Head of IR and Media
Margherita Sacerdoti, +39.0161.487456
Investor Relations Specialist
KEYWORDS: United States Europe North America New York Italy
The article Enzo Biochem's Clinical Lab and Biotech Leader DiaSorin Collaborate to Provide Advanced Clinical Technologies originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.